TherapeuticsMD Inc (NASDAQ:TXMD) traded down 0% during trading on Wednesday . The stock traded as low as $5.00 and last traded at $5.00. 3,096,094 shares were traded during mid-day trading, an increase of 66% from the average session volume of 1,861,814 shares. The stock had previously closed at $5.00.
Several equities research analysts have commented on the company. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Friday, February 9th. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a research report on Thursday, February 22nd. Deutsche Bank set a $9.00 price objective on TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, December 20th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $31.00 price objective on shares of TherapeuticsMD in a research report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $14.50.
The company has a market cap of $1,080.00, a P/E ratio of -13.16 and a beta of 0.99.
In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of TherapeuticsMD stock in a transaction dated Friday, December 8th. The stock was acquired at an average cost of $6.21 per share, with a total value of $31,050.00. Following the purchase, the director now directly owns 3,555 shares in the company, valued at approximately $22,076.55. The acquisition was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 23.92% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. MANA Advisors LLC acquired a new position in shares of TherapeuticsMD during the 4th quarter worth approximately $104,000. Paloma Partners Management Co acquired a new position in shares of TherapeuticsMD during the 4th quarter worth approximately $105,000. Edge Wealth Management LLC raised its stake in shares of TherapeuticsMD by 2,500.0% during the 4th quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock worth $125,000 after buying an additional 20,000 shares during the period. Virtu KCG Holdings LLC acquired a new position in shares of TherapeuticsMD during the 2nd quarter worth approximately $157,000. Finally, Quantbot Technologies LP acquired a new position in shares of TherapeuticsMD during the 3rd quarter worth approximately $189,000. 71.40% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “TherapeuticsMD (TXMD) Trading Down 0%” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3229022/therapeuticsmd-txmd-trading-down-0.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.